From Early Discovery to Global Delivery.

Alpha Genesis partners with biotechnology and pharmaceutical companies at every stage of development, from seed-stage startups to publicly traded industry leaders. Our ability to deliver purpose-bred nonhuman primates, validated bioproducts, and IND-enabling research services with exceptional lead times makes us a strategic asset to industry partners working on accelerated timelines. Whether supporting early preclinical studies or full IND submission packages, our GLP-capable infrastructure, in-house scientific expertise, and compliance with USDA, OLAW, and AAALAC standards ensure that clients receive reliable, audit-ready data. Many of the companies we support have gone on to achieve successful Series A and B funding rounds, file IND applications, and pursue initial public offerings, with programs designed to bring transformative therapies to patients. With a commitment to speed, precision, and discretion, Alpha Genesis enables therapeutic innovation in areas ranging from oncology and gene therapy to neurodegeneration and infectious disease. We are proud to support companies whose breakthroughs are reshaping the landscape of human health.